logo
Plus   Neg
Share
Email

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Harley-Davidson Inc. (HOG) disclosed in a regulatory filing that it will be implementing a plan to shift production of motorcycles for the European Union destinations from the U.S. to its international facilities to avoid European Union's tariff. The company expects ramping-up production in international... Want to know when you will die? Google can tell. Google has tested an artificial intelligence or AI computer system that can predict whether hospital patients will pass away 24 hours after admission. Not just that, the system can also guess the length of a patient's stay in hospital and his chances of being readmitted. Piper Jaffray analyst Michael Olson said Monday that the video-game industry revenue could be 100 percent digital by 2022 and result in publisher margins being "dramatically higher." According to Olson, an all-digital video game world would be a tailwind for publishers like Activision Blizzard Inc., Electronic Arts Inc. and Take-Two Interactive Inc.
Follow RTT